Research programme: plasminogen based therapeutics - Omnio/ProMetic Life Sciences

Drug Profile

Research programme: plasminogen based therapeutics - Omnio/ProMetic Life Sciences

Latest Information Update: 09 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Omnio AB
  • Class Blood products and substitutes; Plasminogen activator enzymes; Proteins
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ear disorders
  • Research Diabetic foot ulcer; Inflammation

Most Recent Events

  • 06 Sep 2016 ProMetic Lifesciences plans to file a clinical trial application in Sweden for Ear disorders (Tympanic membrane perforations)
  • 06 Sep 2016 ProMetic Lifesciences plans a trial in Ear disorders (Tympanic membrane perforations) in Sweden
  • 01 Jan 2016 Preclinical trials in Ear disorders in Sweden (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top